Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
- 1 May 2009
- journal article
- research article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 42 (3) , 247-251
- https://doi.org/10.1016/j.bcmd.2009.01.002
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Guideline recommendations for heart complications in thalassemia majorJournal of Cardiovascular Medicine, 2008
- Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 2008
- Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunctionJournal of Cardiovascular Magnetic Resonance, 2008
- Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia majorBlood, 2006
- Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical TrialBlood Cells, Molecules, and Diseases, 2002
- Healthy life expectancy in 191 countries, 1999The Lancet, 2001
- Survival in Medically Treated Patients with Homozygous β-ThalassemiaNew England Journal of Medicine, 1994
- SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOADThe Lancet, 1976